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Abstract In non-small cell lung cancer, epidermal
growth factor receptor gene mutations and anaplastic
lymphoma kinase (ALK) gene rearrangements have a
major impact upon the level of response to treatment
with specific tyrosine kinase inhibitors. This review
describes the molecular basis of ALK inhibition, sum-
marizes current data on the effectiveness and safety of
ALK inhibition therapy, describes the different testing
methodologies with their advantages and disadvantages,
provides a suggested testing algorithm and puts forward
a proposal for an external quality assessment program in
ALK testing.
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Introduction
In 2008, lung cancer was the most commonly diagnosed
cancer and caused the highest number of cancer-related
deaths [1]. Currently, only 10–15 % of lung cancer patients
will be cured [2]. Strategies to maximize treatment benefit
have centred on individualizing treatment according to the
molecular profile of the disease [3, 4]. Mutations of the
epidermal growth factor receptor (EGFR) gene have a major
impact upon the level of response to treatment with tyrosine
kinase inhibitors [5]. In addition to mutations in the EGFR
gene, alterations in hepatocyte growth factor receptor
(MET), vascular endothelial growth factor (VEGF), VEGF
receptor, GTPase KRAS (KRAS), receptor tyrosine protein
kinase erbB-2 (HER2), echinoderm microtubule-associated
protein-like 4-anaplastic lymphoma kinase (EML4-ALK),
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha isoform, serine/threonine protein kinase B-raf,
insulin-like growth factor 1 receptor [6], ROS1 [7], and the
KIF5B and RET fusion gene [8, 9] have also been implicated
as oncogenic drivers in the pathogenesis of non-small cell
lung cancer (NSCLC), especially adenocarcinoma.
In 2007, Soda et al. [10] reported that a small inversion
within chromosome 2p results in the formation of a fusion
gene comprising portions of the EML4 gene and ALK in
NSCLC cells. A recently developed MET inhibitor (PF-
02341066, crizotinib; Pfizer) was shown to also inhibit ALK
[11, 12]. Phase I [13, 14] and II [15, 16] studies have revealed
encouraging data [14], leading to an accelerated approval of
crizotinib by the FDA in August 2011 [16]. Pathologists will
play a key role in the identification of aberrations of ALK in
NSCLC. The aim of this article is to provide information on
how ALK alterations in NSCLC can be detected, with an
emphasis on the uncertainties regarding methodology.
Molecular basis of ALK inhibition therapy
Transforming rearrangements of the ALK gene were first
identified in anaplastic large cell lymphomas [17, 18], and
subsequently in inflammatory myofibroblastic tumours [19]
and a subset of NSCLC [10]. An inversion event on the
short arm of chromosome 2, resulting in the fusion of ALK
gene with the EML4 gene locus, is the most common
aberration of the ALK gene in lung cancer (Fig. 1) [10].
This rearrangement leads to the production of a chimeric
protein, which has constitutive ALK kinase activity [14].
Over ten EML4-ALK variants have been identified in lung
cancer so far, as well as other fusion partners TFG and
KIF5B [20]. In addition, as single fluorescence in situ hy-
bridization (FISH) signals (3′) are also associated with a
positive response to crizotinib treatment, it seems that small
deletions of 5′ end of the ALK gene may also occur [14, 21].
Current estimates suggest that the EML4-ALK fusion is
present in approximately 3–6 % of adenocarcinomas,
depending upon on the population studied and the ALK
detection methods used [22, 23].
Clinical characteristics associated with the EML4-ALK
gene fusion are adenocarcinoma histology, never/light
smoking history and younger age [24–26]. However, these
characteristics are not shared by all carriers. The ALK
fusion has also been detected in older patients (aged
76 years) with a smoking history [24]. Therefore, clinical
characteristics are insufficient and molecular testing is nec-
essary to determine ALK status [27].
ALK-positive tumours have been detected in all histolog-
ical subtypes of adenocarcinoma, but especially in solid
signet-ring cell and mucinous cribriform patterns [24, 28–31].
Effectiveness and safety of ALK inhibition therapy
Crizotinib is the most advanced ALK inhibitor in clinical
development [3]. In ALK-positive patients (n0119), an
Fig. 1 Signal pattern of Vysis ALK Break Apart FISH Kit. ALK and
EML4 are located on chromosome 2p21–2p23. Note that EML4 is
normally on the opposite strand to ALK, and that both probes on the
ALK gene (red orange and green) are close together, explaining the
FISH fusion signal. The EML4-ALK fusion gene is the result of an
inversion of the N-terminal portion of EML4 with the kinase domain of
ALK [10]. This inversion leads to an increased distance between the
red orange and green probes. A deletion of the proximal part combined
with the inversion explains the single red orange signal. The EML4-
ALK fusion protein has a fully functional ALK kinase domain and has
gain-of-function properties [5, 10]. Cells are considered ALK FISH
positive when there is: (1) ≥1 set of red and green signals that are ≥2
signal diameters apart, or (2) a single red signal without a
corresponding green signal in addition to fused (normal) signals. A
sample is considered negative if <5 cells (<10 %) are positive and
positive if >25 cells (>50 %) are positive. A sample is considered
equivocal if 5–25 cells (10–50 %) are positive
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overall response rate (complete responses + partial
responses) of 61 % (95 % CI, 52–70 %), a clinical benefit
rate (complete responses + partial responses + stable dis-
ease) of 88 % and a preliminary median progression-free
survival of 10 months (95 % CI, 8–15 months) have been
shown [13]. The median overall survival has not been
reached. In a retrospective case-match analysis, Shaw et al.
[32] found that ALK-positive NSCLC patients had a longer
overall survival rate after crizotinib as second- or third-line
therapy. Crizotinib seems to show poor penetration of the
blood–brain barrier [33].
Crizotinib is well tolerated, with reported treatment-
related adverse events of nausea (46 %), vision disorder
(45 %), vomiting (39 %) and diarrhoea (29 %), mostly of
grade 1/2. Grade 3/4 adverse events were reported in 15 %
of patients (mostly increased alanine aminotransferase,
dyspnoea and neutropenia) [13].
A proportion of ALK-positive patients with NSCLC
(in most studies <10 %) continue to show progressive
disease in spite of crizotinib treatment [15, 34]. Several
mechanisms of resistance have been suggested to ex-
plain this lack of efficacy: (1) ALK kinase domain
mutations (found in 4/11 samples); (2) copy number
gain of the ALK gene rearrangement (found in 2/11
samples); (3) EGFR/KRAS mutations (found in 3/11
samples) [35]. Some patients never showed (intrinsic
resistance) and some initially showed (acquired resis-
tance) a response to treatment [35].
Neither percentage of positive cells nor signal copy num-
ber appears to be predictive of benefit from ALK inhibition
treatment [21]. In other words, using ALK FISH, there is no
greater likelihood of a treatment response to crizotinib in a
patient with a sample showing nearly 100 % positivity than
for a patient with a sample showing just above the positivity
threshold. However, it is still important to know the percent-
age of positive cells to determine whether the threshold has
been reached.
Detection of ALK gene rearrangements
Increasing availability of targeted agents with selective bio-
markers has introduced new challenges in NSCLC diagnosis
[36]. Issues related to small sample diagnostics, the interac-
tion between pulmonologists and pathologists, tissue man-
agement and required clinical information have recently
been described [37]. Current diagnostic approaches to detect
ALK rearrangements include immunohistochemistry (IHC),
FISH and reverse transcriptase polymerase chain reaction
(RT-PCR). Unpublished information from pilot studies sug-
gests that ALK fusions may be demonstrated with massive
parallel sequencing. However, sufficient details for an ade-
quate comparison with FISH are currently lacking.
Tissue management
With personalized tumour medicine in mind, tissue sample
size should be maximized whenever feasible. In addition,
tissue handling, processing and sectioning should be stan-
dardized to minimize wastage and optimize use of tissue for
staining procedures and PCR-based molecular tests. Histo-
logical and cytological specimens are both potentially suit-
able for ALK testing. Currently, the only clinically validated
test to determine ALK status is the Vysis/Abbott ALK FISH
break apart test. However, this test and the interpretation
algorithm are only designed and validated for histopatho-
logical use on intact formalin-fixed paraffin-embedded
(FFPE) tissue biopsies or resection specimens. If cytological
material is to be used, laboratories must take steps to vali-
date their testing methodology.
Tumour tissue should preferentially be taken from
metastases if access is less dangerous. Sampling of
these sites ensures that the more important fraction of
total tumour cell burden is collected. Furthermore, potential
heterogeneity problems within the primary tumour are
avoided when sampling metastases.
Standardized tissue and cell processing
Tissue handling steps have recently been described [37].
While so-called ‘reflex’ IHC and molecular testing provides
a rapid diagnosis, it should be avoided if tissue resources are
marginal. In anticipation of obligatory biomarker testing, an
algorithm for reflex block cutting could be employed.
If the initial tissue sample is small, some (three to four)
additional sections (extra spare cut sections) may be taken to
avoid tissue loss by recutting. The quality of some epitopes
and DNA/RNA may be lost (within hours/days) when sec-
tions are not immediately used [38–40]. Various treatments
for the cut sections may prevent oxidation [37].
An algorithm that laboratory staff may find useful when
handling lung biopsies is presented in Electronic supple-
mentary material (ESM 1).
Clinical diagnostic tests
IHC
Immunohistochemical detection of the ALK protein has
considerable potential as a screening tool to test NSCLC
samples for ALK rearrangements. The biological premise is
that the translocation or inversion of part of the ALK gene
with its numerous possible partners leads to over-expression
of the ALK protein, and therefore overactivity of the ALK
tyrosine kinase. This protein ALK tyrosine kinase is the
target of crizotinib. It therefore makes sense to assess the
drug target directly.
Virchows Arch (2012) 461:245–257 247
IHC has several advantages over either an ISH method
(especially when based on fluorescent probes) or an ap-
proach based upon mRNA (RT-PCR) to detect the actual
rearrangement. These advantages are that it is cheap, rapid
and easily integrated into a diagnostic protocol and familiar
to all pathologists. Although IHC is only minimally quanti-
tative, in practice it is used as a semiquantitative test [41].
However, challenges with IHC are: (1) the tissue prepara-
tion; (2) the choice of antibody; (3) the signal enhancement
system; (4) the scoring system.
Pre-analytical phase Currently, the role that pre-analytical
issues, like fixative and duration of fixation, may have on
ALK epitope preservation has not been evaluated. However,
compared to what has been observed for other antibodies
[39], here the pre-analytical steps appear to be particularly
critical and mistakes are irremediable. False-negative cases
may be due to poor fixation. Such issues may be of partic-
ular concern in surgically resected tumours, where a gradi-
ent in positivity can be observed due to the gradient in
fixative penetration in the sample [42]. Ultimately, any test
for abnormal ALK genes in NSCLC is likely to be most
important in small biopsy or cytology samples, where intra-
sample heterogeneity is less likely to be appreciated because
fewer cells are present, but where the possibility of hetero-
geneity of expression may lead to a false-negative test.
Analytical phase One of the particular challenges in IHC
detection is that the protein concentrations in ALK-
rearranged NSCLC are relatively low. Standard detection
methodology, as used in the identification of ALK-
rearranged anaplastic lymphomas, is inadequate for the
detection of all cases of ALK-rearranged NSCLC. Cur-
rently, there are three primary antibodies commonly
referred to in the published literature; clone 5A4 (Novo-
castra, Leica, but also available pre-diluted from
Abcam), ALK1 (Dako) and D5F3 (Cell Signalling Tech-
nology). Experience with the first two antibodies is
widest, and more success (and excellent comparison
with the outcome of FISH testing for the rearrangement)
has resulted from their use with detection systems with
a substantial degree of signal amplification (Leica/Novo-
castra Novolink, Dako Advance, Tyramide, Envision+,
Ventana i-view). For more details, see Tables 1 and 2. If
using FISH as the gold standard, use of these antibodies in this
way has resulted in both a very high negative predictive value
(all IHC-negative cases are also FISH-negative) and high
positive predictive values (90–100 % probability of being
FISH positive when IHC is strongly positive) [23, 24,
43–51]. For more details, see “Concordance between IHC
and FISH” section. Good concordance has also been shown
between RT-PCR and the antibodies ALK1 [22, 44] and 5A4
[45]. With current knowledge, all IHC positive (+/++/+++)
cases would be best screened with FISH to confirm probable
rearrangement.
In the literature (Table 1) and in the experience of the
authors, there is some variation in the best concentrations of
various primary antibodies and the antigen retrieval meth-
odology. Personal experience with the 5A4 clone has found
better results with pH6- when compared to pH9-buffered
solution.
Comparing primary antibodies is very difficult since
there are few published studies with comparative data. One
study did compare the D5F3 clone with the ALK1 clone and
found the former far superior [49], but the latter was not
used with any special detection amplification. At this mo-
ment, it is very difficult to reach a conclusion from the
literature; there may be a marginally better performance
from the 5A4 clone when compared to the ALK1 clone,
borne out by anecdotal experience, but it must be empha-
sized that other variations in study methodology make com-
parison problematic.
Post-analytical phase In NSCLC, ALK-rearranged staining
is cytoplasmic. It may have a granular character, and in
some cases there may be membrane accentuation. Opinions
differ as to the degree of staining heterogeneity that may be
encountered. Whilst some assert that it is generally homo-
geneous in tumours, others, including the authors, have
certainly seen variation in staining intensity in sections of
surgically resected tumours (see comment above regarding
fixation).
One of the most neglected issues in the literature is the
question of definitions of degree of staining. Many studies
do not even indicate how different grades of staining were
defined. There is no clear consensus on this matter. Prospec-
tively, it may be of value to determine a so-called histoscore
(H-score) utilizing the proportion of tumour cells showing
each different intensity (+, ++ and +++) of staining. Assess-
ment of staining intensity is very subjective. The use of
successive microscope objectives with related spatial reso-
lutions as a physical aid in establishing intensity (as first
applied on HER2 by Ruschoff et al. [50]) may lead to more
uniformity in intensity scoring. Strong staining (+++) is
clearly visible using a ×2 or ×4 objective, moderate staining
(++) requires a ×10 or ×20 objective to be clearly seen,
whilst weak staining (+) cannot be seen until a ×40 objective
is used. This approach is called the modified H-score. Fre-
quently used scoring systems are presented in Table 2.
For the time being, the modified H-score is recommen-
ded because it will allow sufficient detail for comparison
with other studies. It may turn out that a more simplified
scoring system is suitable as well. Ultimately, studies are
required where prospectively determined IHC scores can be
directly related to clinical outcomes in patients treated with
crizotinib.
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Pathologists should be aware of various artefacts that
may lead to false-positive staining; these are generic issues,
not necessarily specific to ALK IHC. The possibility of
false-negative tests can be guarded against, at least to some
extent, by the use of positive control material with every test
staining run. Such material may not be readily available, and
it is important that the control material is from ALK-
rearranged NSCLC or similar and has the same levels of
ALK protein epitopes. ALK-rearranged lymphomas are not
suitable as a control because he protein epitope level is
much higher than in NSCLC, thus giving false confidence
of sufficient staining.
FISH
The majority of clinical studies examining ALK muta-
tions have used FISH. In the USA, prescription of
crizotinib is dependent upon the use of the Vysis ALK
Break Apart FISH Probe Kit (Abbott Molecular, Inc.)
[16]. Although FISH can be performed on FFPE tumour
specimens and detect multiple ALK fusion variants [28],
there are various challenges related to the FISH tech-
nique, e.g. the break apart red and green signals indi-
cating ALK rearrangements (Fig. 2) can be subtle and
occasionally difficult to recognize.
Pre-analytical phase A protocol for cytology is provided in
ESM 2.
Processing and sectioning—For an effective procedure
for surgical specimens, it is recommended that embedded
tissues do not exceed 2 cm in length and 3 mm in thickness.
Samples should be processed according to a standard
protocol.
In practice, ALK testing works well on 3- to 5-μm
sections. A minor preference exists for a thickness of
5 μm. Sections should be mounted on coated slides to
prevent cleavage artefacts and washing off during the pro-
cedure. Sections should be dried at 60 °C for 1 h or at 45 °C
overnight.
The maximum storage time for tissue or cell block sec-
tions should be 1–6 months (based on the authors' experi-
ence) and 6–12 months for conventional cytological
specimens [52] to avoid hybridization failure and either
false-negative or false-positive results. A protective coating
Table 1 IHC protocols described in the literature
Antibody Source HIER Dilution Incubation Detection system
Yi et al. [46] ALK1 Dako EDTA, pH 8, 30 min 1/100 30 min at RT Advance (Dako)
Yang et al. [43] ALK1 Dako EDTA, pH 8, 30 min 1/100 30 min at RT Advance (Dako)
Paik et al. [47] 5A4 Abcam CC1 (Ventana), 1 h 1/30 2 h at 42 °C i-view (Ventana)
McLeer-Florin et al. [48] 5A4 Abcam CC1 (Ventana), 1 h 1/50 2 h at 37 °C i-view (Ventana)
Hofman et al. [45] 5A4 Abcam pH 9, 40 min, 97 °C 1/50 30 min RT EnVision Flex (Dako)
Kim et al. [27] 5A4 Novocastra CC1 100 °C, 20 min 1/30 2 h at 42 °C i-view (Ventana)




HIER heat-induced epitope retrieval, EDTA ethylenediaminetetraacetic acid, RT room temperature, CST cell signaling technology
a For anaplastic large cell lymphomas
b For lung adenocarcinomas and inflammatory myofibroblastic tumours
Table 2 IHC scoring systems
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a Average of 14.7 % positively stained cells
b Average of 58.2 % positively stained cells
c Average of 97.3 % positively stained cells
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of paraffin to histological sections prevents loss of antige-
nicity caused by photo-oxidation and drying of the tissues
[37]. In order to avoid problems of irregular or background
staining of histological specimens, it is essential to depar-
affinize the samples properly [37].
Relocation of tumour cells by a software-driven automat-
ed stage is highly desirable for ‘restrained’ cytological
specimens with a tumour cell proportion of <50 %. This
allows precise distinction of the tumour cells from admixed
benign cells and facilitates review of the results at the
microscope.
Analytical phase
Method—Use of diagnostic kits certified by the FDA
(Abbott Vysis ALK Break Apart FISH Probe Kit,
Abbott Molecular, Inc.) is recommended. The package
insert contains a detailed protocol of the technical pro-
cedures and interpretation. In practice, the Vysis kit has
some limitations: (1) appropriate optical filters are
required for the probes used; (2) the green signal
may fade earlier than the red signal, increasing the
likelihood of false-positive single-red signals. Other,
not yet FDA-approved, FISH assays are commer-
cially available (e.g. ZytoLight® SPEC ALK/EML4
TriCheck™ Probe, ZytoVision). Every assay should
undergo validation in the laboratory before clinical
implementation. This validation can be conducted
with five to ten positive and five to ten negative
cases. The results are compared with a reference
centre, and concordance of at least 95 % should
be obtained. In addition, laboratories should
participate in external quality assessment schemes
as soon as they become available. When a labora-
tory authorized to conduct FISH adopts another
bright-field ISH for diagnostic purposes, an internal
validation can be conducted in the laboratory com-
paring the new technique with FISH. Again, a con-
cordance of 95 % must be obtained. This 95 %
threshold may change in time, after more experi-
ence is gained with the external quality assessment.
The use of standardized kits requires strict adher-
ence to the manufacturers' instructions, i.e. without
any deviation.
A minimum norm for ALK experience is not
known yet, but for Her2 it was suggested that at
least 150 ISH cases per annum (minimum of 100
breast and 50 gastric cases by ISH per annum)
would be the optimal volume to ensure quality
and cost effectiveness [53] (see “Proposal for an
external quality assessment program” section).
The number of annual tests considered optimal
for guaranteeing the technical sufficiency of a lab-
oratory is 150 ISH tests on any type of tumour
[51]. Analysis of complete histological sections is
recommended in order to minimize signal loss on
the Z-axis. In FISH procedures, it is essential to use
fluorescence filters with excitation and emission
wavelengths appropriate to the fluorochromes of
the probes contained in the kit.
Controls—With ISH techniques, the case for study
serves as a control when consistently presenting sig-
nals, both in tumour cells and in the accompanying
normal cells. Nevertheless, the use of separate controls
is strongly advised. A pre-hybridization assessment of
digestion is useful in difficult samples (e.g. very small
biopsies with low tumour content).
Post-analytical phase
Assessment of the results—A pathologist should inter-
pret the results. When other persons score the speci-
mens, they should be well trained and experienced in
histo- and cytomorphology. In such a case, a patholo-
gist should coordinate, validate, review and sign off the
interpretation. A total of 50 nuclei should be scored
using an epifluorescence microscope equipped with a
DAPI, a Spectrum Orange, Spectrum Green and
double-filter set, using a ×60–100 oil immersion objec-
tive lens. The spectral orange probe is mostly called the
‘red probe/signal’ in the literature, and this terminology
has been used throughout the manuscript.
Assessment must be conducted exclusively on nuclei
with sufficient hybridization quality, in a consecutive
Fig. 2 Representative examples of ALK FISH findings in three pul-
monary adenocarcinomas (Vysis ALK Break Apart FISH probe). All
three carcinomas show increased ALK copy number. a Normal signals,
no rearrangement. Note that some of the signals are fused and produce
a yellow signal, while others have green and red signals in close
proximity. b One or two break apart signals per nucleus, indicative of
inversion. c Single red signals, indicative of inversion and deletion.
Note that the cancer cells in b and c contain both rearranged and
normal ALK signals. Cells are considered ALK FISH positive when
there is: (1) ≥1 set of red and green signals that are ≥2 signal diameters
apart, or (2) a single red signal without a corresponding green signal in
addition to fused (normal) signals. A sample is considered nega-
tive if <5 cells (<10 %) are positive and positive if >25 cells
(>50 %) are positive. A sample is considered equivocal if 5–25
cells (10–50 %) are positive
250 Virchows Arch (2012) 461:245–257
manner, and with the microscope focus adjusted to each
nucleus in order to correctly identify all the signals
present in the nucleus of the cells.
When conducting FISH as an ISH technique, given
the difficulty of dark-field assessment, the following are
recommended:
a. Cells are considered ALK FISH positive when: (1)
at least one set of red and green signals have a
distance between the signal borders of ≥2 diameters
of the largest of the two signals (break apart of the
two differently coloured probes indicates gene fu-
sion by inversion), or (2) when there is a single red
signal without a corresponding green signal in ad-
dition to fused (normal) signals (indicating gene
fusion by inversion and deletion) (Figs. 1 and 2). Note
that a single green signal without a corresponding red
signal is considered negative. Similarly, an increased
copy number of non-rearranged ALK genes with
fused signals corresponds to polysomy of chromo-
some 2 or ALK amplification, but is negative for
rearrangement.
b. A sample is considered negative if <5 cells (<10 %)
are positive and positive if >25 cells (>50 %) are
positive.
c. A sample is considered equivocal if 5–25 cells (10–
50 %) are positive. In this case, a second reader
should evaluate the slide. If the average of the two
readings contains at least 15 % positive cells, the
sample is considered ALK FISH positive. It should
be kept in mind that the digestion time needs to be
adjusted for some samples. Examples of typical
FISH findings are shown in Fig. 2.
During interpretation, the spatial distribution of
the distance between the two signals in the Z-direc-
tion also needs to be taken into account. In cases of
only one signal, adjusting the plane of focus (by
turning the microscrew) is frequently necessary
when using the conventional FISH microscope. An
advantage of a digitized automatic FISH analysis
system is that fluorescent images may be com-
pressed in the Z-direction (Z-stacks), often making
this automated stage more convenient than live mi-
croscopy. The presence of all signals in one hori-
zontal plane facilitates scoring and review, and
allows permanent documentation. In our experience,
a positive scoring result that cannot convincingly be
illustrated by fluorescence photography is of ques-
tionable value.
Cytological specimens offer the advantage of
analysing entire cells/nuclei containing all chromo-
somal signals. Instead, a part of the nuclei in histo-
logical tissue sections are truncated, leading to a
lower number of fluorescence signals, and this ef-
fect depends on the section thickness.
Note that in most ALK-positive samples, not all
alleles are abnormal (e.g. only one in a disomic cell
or one or two in tetrasomic cells). Typically, there is
one predominant type of rearrangement in one sam-
ple (either break apart or deletion). Great variability
in signal patterns within one sample might suggest
technical artefacts.
There is evidence that ALK rearrangements are
truly diffuse rather than heterogeneous within ALK-
positive tumours [21, 54]. First, IHC typically
shows diffuse ALK expression in ALK-positive
tumours [47, 55]. Second, the distribution of cell
positivity by FISH is diffuse; there are no discrete
foci of ALK rearrangements within a tumour [21,
54]. This suggests that any observed variability is
not biological, but rather caused by technical
factors.
Given the presumed homogeneous distribution
of ALK rearrangements, the percentage of FISH-
positive cells in an ALK-positive tumour lying
between 20 and 80 %, and not reaching 100 %
may appear contrary. The ‘single red’ signal is
found in a higher fraction of tumour cells than
the ‘break apart’ signal [21]. This discrepancy
can readily be explained by the distribution of
signals in three-dimensional space and their pro-
jection by the assessing pathologist to the hori-
zontal plane. A separated signal can be located
anywhere on a virtual sphere around the other
signal. In a disomic tumour cell with one rear-
ranged ALK gene copy, the probability of
detecting break apart signals in the two-
dimensional projection may therefore not exceed
25–30 %.
In the authors' experience, the minimum num-
ber of tumor cells required in histological speci-
mens is at least 100, as approximately half will
not be stained with the fluorescence probes for
reasons related to the stereological analysis. Less
than 40 tumor cells/neoplastic nuclei with FISH
signals are unreliable for determining positivity.
Increased ALK gene copy number (3 to >6
gene copies), which is mostly due to polysomy
of chromosome 2, has been reported in 80 % of
NSCLC [56]. In cases of polysomy, one rear-
ranged signal per nucleus is sufficient for a
‘positive’. High gene copy number of non-
rearranged ALK does not appear to influence
response to crizotinib. A possible predictive val-
ue of the copy number of the rearranged ALK
gene in tumour cells and its influence on the
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level of ALK protein expression remains to be
investigated.
Overall, interpretation of the ALK FISH anal-
ysis is more complex than for other FISH
assays, e.g. with amplifications or interchromo-
somal translocation. This is due to the fact that:
(1) fusion inversion occurs on the same chromo-
some arm—in contrast to fusion processes in
SYT-SSX and BCR-ABL FISH tests, for exam-
ple, where genes from different chromosomes
are involved; (2) in some ALK wild-type cells
(especially with larger nuclei or after prolonged
digestion) the red and green signals may be
slightly separated and the fusion to yellow fluo-
rescence is not apparent; (3) the process of cut-
ting and subsequent signal separation may lead
to a low number of false-positive break apart
signals in cells without the ALK fusion. These
characteristics mean that a low threshold of pos-
itive cells can still select patients who will react
to ALK inhibitor treatment. However, this com-
plexity highlights the need for specific training
and experience with ALK FISH.
Personnel—The number of laboratory technicians who
conduct tests and the number of pathologists who in-
terpret them must be as low as possible in order to
guarantee the effectiveness of the undertaking. Both
the technicians and the pathologists must have under-
gone training. For assessing the post-analytical
(interpretation) phase, correlation with the reference
result of at least 95 % in 10–20 cases is recommended.
Periodically, the aforesaid training should be refreshed
in dedicated working sessions.
Report—While the report should be adapted to the
different information systems used in different hospi-
tals, it must include, at minimum, the data presented in
Table 3. The recommended turnaround time is <7
working days.
FISH is not feasible in all laboratories and the results are
not always clear. McLeer-Florin et al. [48] reported that
19 % of cases analyzed by FISH were not interpretable.
Concordance between IHC and FISH
The results from the three larger FISH/IHC concordance
studies have shown that in FISH-negative cases, IHC is
always negative (i.e. 100 % concordance) [46, 47, 57]. This
complete concordance is also seen between a positive FISH
result and an IHC 3+ score [46, 47, 57]. Very good concor-
dance levels between FISH and IHC have also been dem-
onstrated by Jokoji et al. [58]. McLeer-Florin et al. [48] also
found good concordance between FISH and IHC. In their
research, the Novocastra 5A4 antibody was used. The
authors suggested using IHC to evaluate the cases that were
not interpretable by FISH.
Some of the panel have had different experiences: name-
ly that it is possible to have a sample that is IHC 3+ and
FISH negative. In one such patient, a response to Crizotinib
was seen (E.T.). Also a sample may be FISH positive and
IHC negative. Some discordant results have been observed
in tumours expressing ALKwith a weak (1+) to moderate (2+)
signal. Table 4 provides a summary of published articles
comparing ALK analysis by FISH and IHC.
PCR-based molecular assays
RT-PCR provides a highly sensitive technique in which a
very low copy number of RNA molecules can be detected.
As for EML4/ALK the forward and backward primers are




Identification of doctor making request
Dates of request and test
Identification of sample (case and block number)
Type of samplea
Anatomical origin
Gross specimen handling/molecular method
Date block received by laboratory
Block used for analysis
Probe used (supplier, approval by FDA or other agency)
Method of assessment (semi-quantitative, image analysis)
Threshold for positivity
Microscopy/molecular results
Number of nuclei assessed
Results
Positive (%)
Presence or absence of patterns indicating rearrangement
(specify whether split or single)
Negative (% of translocated cells, if any)
Presence or absence of patterns indicating rearrangement
Inconclusive: Explanations for inconclusive answersb
Conclusion
Molecular test outcome and interpretation
Rearrangement associated with sensitivity
Name and signature of the pathologist(s) responsible for the
investigation
a For example, bronchial–transbronchial biopsy, surgical specimen,
core needle biopsy, transbronchial fine needle aspiration, effusion
cytology or other
b For example, possible false-negatives due to low fraction of tumour
cells or uncertain fixation time
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Table 4 Summary of published articles comparing ALK analysis by FISH and IHC





FISH IHC FISH IHC
Shaw et al.
[25]
ALK1 Dako n.a. NSCLC,
141








6 (1.8 %) n.a. n.a. The 6 cases testing positive using IHC
were positive with FISH. 8 of the IHC
ALK− cases were also tested using







20 (5.6 %) n.a. n.a. n.a. 8 of the 10 FISH ALK+ cases with
sufficient tissue were also IHC ALK+
(sensitivity080 %); 1 case ALK– by











n.a. n.a. n.a. Sensitivity and specificity of IHC were
67 and 97 %, respectively






n.a. n.a. n.a. Sensitivity and specificity of IHC were
100 and 99 %, respectively
Yi et al.
[46]
ALK1 Dako Advance Adeno,
101






Of the 10 FISH+ cases, 8 were IHC 3+,
1 was IHC 2+ and 1 was IHC +; of
the 91 FISH– cases, 2 were IHC 2+,
20 were IHC 1+, 69 were IHC 0;
sensitivity and specificitya of IHC
were 90 and 97.8 %, respectively
Paik et al.
[47]








Of the 19 FISH+ cases, 16 were IHC 3
+, 3 were IHC 2+; of the 434 FISH−
cases, 7 were IHC 2+, 14 were IHC 1
+, 413 were IHC 0; sensitivity and









n.a. 12 (3.5 %) n.a. n.a. All these 12 IHC ALK+ cases were also
FISH ALK+; all IHC ALK– cases




D5F3 Cell ST n.a. NSCLC,
71
6 (8.5 %) n.a. n.a. n.a. All FISH ALK– negative cases were
also IHC ALK–. 4/6 FISH ALK+
cases were also ALK IHC+; 1 case




5A4 Novocastra n.a. NSCLC,
735




Of all cases, 15 were IHC 3+, 20 were
IHC 2+, 20 IHC 1+, 700 were IHC0;
all IHC0/1+ were ALK FISH–, all
IHC 3+ cases were ALK FISH+, and
13 of the 20 IHC 2+ were FISH+;
sensitivity and specificitya of IHC
were 100 and 96.2 %, respectively
Adeno,
395






5A4 Abcam i-view Adeno,
441
n.a. 29 (6.5 %) n.a. n.a. Of 81 cases with interpretable IHC and
FISH results, 21 were FISH ALK+;
of these 21 cases, 19 were IHC ALK+
and 2 were IHC doubtfully positive;
of the 60 FISH ALK– cases, 1 was
IHC ALK+ and 59 were IHC ALK–
Yang et al.
[43]










All IHC 0 cases were FISH ALK– and
all IHC 3+ were FISH ALK+; 96.9 %
of IHC 1+ cases were FISH ALK−
and 85.7 % of IHC 2+ cases were
FISH ALK+
IHC scores of 0 and 1+ are regarded as negative; scores of 2+ or 3+ as positive
Adeno adenocarcinomas, ALK anaplastic large cell kinase, FISH fluorescence in situ hybridization, IHC immunohistochemistry, n.a. not available,
NSCLC non-small cell lung cancer, ALK+/– positive/negative results for ALK rearrangement
a Using FISH as the gold standard
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complementary to gene fragments, which are normally on
opposite strands, the specificity is high. RT-PCR can be
used on mRNA/cDNA to directly detect EML4-ALK;
hence, it does not suffer from the problems inherent in
interpreting FISH or IHC. Therefore, it has been used as a
gold standard to assess the sensitivity and specificity of IHC
[55], FISH [55, 59] and CISH [27, 59]. It has also been used
as a stand-alone test instead of FISH or IHC [60].
However, RT-PCR has several disadvantages that make it
unlikely to become the standard test for this mutation.
Firstly, good quality RNA is required [59]: some of the
amplicons are more than 1,000 bp in size and require proper
cryopreservation of tumour samples that may be lacking in
routine practice [55]. In FFPE sections, RT-PCR above
300 bp is not reliable. Secondly, multiplex systems are
required because of the wide variations in fusion types
[59]. Thirdly, only known alterations can be tested (at least
10 are currently known for ALK) [20]. Furthermore, the
clinical relevance of multiplex RT-PCR is unclear because
so far in all clinical trials FISH has been used to identity
ALK-positive patients. RT-PCR is included in the diagnostic
algorithm proposed by Just et al. [55], but only after IHC
and FISH have been performed, and only as a source of
further information on the ALK fusion variant and expres-
sion level, rather than for diagnosis.
RT-PCR for ALK mutation testing is being offered by
some commercial vendors (e.g. Response Genetics, Inc., in
the USA); however, it is not clear how reliable these tests
are. The panel strongly suggested that any such tests should
involve pathologists early in the development and should be
diagnostically orientated.
Testing algorithm
In the National Consensus from Spain [61], ALK rearrange-
ment testing is recommended in patients with advanced
NSCLC who are negative for the EGFR mutation (all histo-
logical subtypes in non-smokers; non-squamous-cell carcino-
ma subtype in current or ex-smokers). In contrast, the most
recent NCCN guidelines (version 1.2012) [62] recommend
ALK rearrangement testing concurrent with EGFR mutation
testing for adenocarcinomas, large cell carcinomas and
NSCLC NOS. This differs from recent guidelines in Switzer-
land [63] and France (French National Cancer Institute; INCa)
[48] proposing ALK testing only by FISH and only in EGFR-
negative KRAS-negative adenocarcinoma patients.
Since phase II and III clinical trials with crizotinib in
ALK-positive patients have used FISH, this technique
should be considered the ‘gold standard’ for determining
ALK positivity. However, following successful validation
with large series and different antibodies, IHC could also
become a good screening method.
The authors agree that more data for an evidence-based
algorithm are needed. It is possible that the algorithm pre-
sented in Fig. 3 may in the future be the algorithm of choice.
Proposal for an external quality assessment program
For optimal ALK mutation testing in NSCLC, the quality of
the sample, the analytical procedure and the reporting of the
test result are crucial (Table 3). European quality assessment
projects will examine different steps of ALKmutation testing.
One important ongoing quality assurance project in
Europe is the FALKE (Fusion of EML4-ALK epidemiology
Evaluation) project. This initiative was set up by the Ger-
man Society of Pathology for German-speaking countries.
The basis of this ring trial is to test 1,000 samples from
NSCLC patients. For the FALKE project, it was decided to
test all NSCLC and not to focus on adenocarcinoma. For all
samples, ALK IHC and ALK FISH will be performed.
In 2012, the European Society of Pathology (ESP) will
run two external quality assessment programs for lung can-
cer. Registration will take place through the ESP website
(QA activities: http://esp-pathology.org/).
In the first round, starting March 2012, ALK FISH and
optional ALK IHC will be offered. The pre-validated tissue
microarray slides will have both positive and negative con-
trols (n ≥10). The second round, in September 2012, will
offer assessment of ALK1, EGFR and KRAS on tissue
microarray samples. Participation is voluntary. Laboratories
meeting the predefined performance threshold will be listed
on the ESP website.
Conclusions
For the personalized treatment of patients with NSCLC, it is
necessary to sample as much tumour tissue as possible.
Fig. 3 Possible ALK testing algorithm in NSCLC if IHC becomes
fully validated
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Adequate clinical information is essential for the optimal
tissue management.
Patients with ALK fusion adenocarcinomas confirmed by
FISH have been shown to respond favourably to crizotinib
treatment, and a phase III trial is currently ongoing. How-
ever, the question of how best to select patients that may
benefit from crizotinib treatment remains to be answered.
There is evidence that IHC could be useful and less
expensive than FISH. Some of the difficulties in interpreting
FISH results may be alleviated by automated procedures.
Whether FISH or IHC becomes the primary method of
ALK mutation testing in Europe, it is clear that rigorous
quality assessment is of the utmost importance to ensure
reliable results and appropriate patient selection.
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